Founded in 2022, is an innovative drug research and development company committed to tackling significant unmet medical needs and advancing global health.
Pamplona Therapeutics utilizes its proprietary ASTRIDE® algorithm platform, which is built on protein structure and Al technology, to accelerate the design of novel therapeutics. Leveraging targeted protein degradation technology, we are committed to developing best-in-class and first-in-class innovative drugs for oncology and autoimmune diseases.
Transform healthcare through groundbreaking innovation
Develop safe and effective therapeutics to improve patients' lives
The founders possess over 30 years of extensive experience in protein structure studies and drug discovery, cultivating a profound understanding of target proteins and drug design.
- Structural biologist, B.S. in Chemistry from Peking University and Ph.D. in Structural Biology from Rutgers University.
- Years of R&D experience at biotech/biopharma Tularik, Amgen.
- Published more than 100 scientific papers and patents, resolved structures of numerous disease-related target proteins, and spearheaded structure-based drug design.
- Member of several professional organizations, including American Crystallographic Society, American Association of Biochemistry and Molecular Biology, Sino-American Medical Association, Chinese Crystallographic Society (Member of the Board of Supervisors), and Protein Data Bank China (Scientific Advisory Board Member).
- Medicinal Chemist, Ph.D. in Organic Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS).
- Awardee, CAS Hundred Talents Program.
- Project leader, National Key Research and Development Program (Ministry of Science and Technology).
- Specializes in small-molecule drug development for cancer and autoimmune therapeutics with advanced expertise in PROTAC and molecular glue technologies.
- 110+ publications (Nat. Med., Nat. Struct. Mol. Biol., J. Med. Chem., Cell Res. et al.), 40+ patents.
- B.S. and M.S. in Chemistry from Peking University, and M.S. in Chemistry from Iowa State University.
- MBA from Pennsylvania State University.
- Over 20 years of experience in innovative drug R&D at GlaxoSmithKline (GSK) and CDMO project management.
- Applied scientific management principles to enhance drug development efficiency through resource integration and risk control, ensuring high-quality project delivery.
- Professor, University of California, San Francisco /HHMI Principal Investigator.
- Elected Member, American Academy of Arts and Sciences.
- Elected Member, the National Academy of Sciences.
- Structural biologist devoting to cryo-electron microscopy and cryo-electron tomography techniques to reveal the physiological functions of biomacromolecular complexes.
- Ph.D. in organic chemistry from the University of Utah.
- Extensive cross-industry experience at Merck, Eli Lilly China, WuXi AppTec, and Biofront biotech.
- 30 years of experience in innovative drug discovery, with a strong focus on inflammation, metabolism, and immunology.
- Expertise in lead compound optimization, candidate drug selection, safety evaluation, IND submissions and full preclinical drug development process.
- Advanced more than 10 clinical candidate drugs.
Room 814, Building 1B,
Weiguang Life Science Park,
Guangming District, Shenzhen, China
info@pamplonatx.com
All rights reserved.
